Mikhail V. Blagosklonny
Brander Cancer Research Institute
New York Medical College
Hawthorne
New York 10532
USA
Name/email consistency: high
- Do cells need CDK2 and ... Bcr-Abl?. Blagosklonny, M.V. Cell Death Differ. (2004)
- Antiangiogenic therapy and tumor progression. Blagosklonny, M.V. Cancer. Cell (2004)
- Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers. Blagosklonny, M.V. Cancer Biol. Ther. (2004)
- Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Blagosklonny, M.V. Cell. Cycle (2004)
- Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Blagosklonny, M.V. Cell. Cycle (2004)
- A new science-business paradigm in anticancer drug development. Blagosklonny, M.V. Trends Biotechnol. (2003)
- Apoptosis, proliferation, differentiation: in search of the order. Blagosklonny, M.V. Semin. Cancer Biol. (2003)
- Cell senescence and hypermitogenic arrest. Blagosklonny, M.V. EMBO Rep. (2003)
- Conceptual research and phenomenology--harmonizing slices. Blagosklonny, M.V. Cell. Cycle (2003)
- Why Iressa failed: toward novel use of kinase inhibitors (outlook). Blagosklonny, M.V., Darzynkiewicz, Z. Cancer Biol. Ther. (2003)
- Cell immortality and hallmarks of cancer. Blagosklonny, M.V. Cell. Cycle (2003)
- Targeting cancer cells by exploiting their resistance. Blagosklonny, M.V. Trends. Mol. Med (2003)
- Matching targets for selective cancer therapy. Blagosklonny, M.V. Drug Discov. Today (2003)
- Oncogenic resistance to growth-limiting conditions. Blagosklonny, M.V. Nat. Rev. Cancer (2002)
- Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Blagosklonny, M.V., Robey, R., Sheikh, M.S., Fojo, T. Cancer Biol. Ther. (2002)
- Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Blagosklonny, M.V. Oncogene (2002)
- Combining phorbol ester (PMA) with UCN-01: fueling fire with water. Blagosklonny, M.V., Conney, A.H. Cell. Cycle (2002)
- Four birds with one stone: RAPA as potential anticancer therapy. Blagosklonny, M.V., Darzynkiewicz, Z. Cancer Biol. Ther. (2002)
- Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Blagosklonny, M.V., Darzynkiewicz, Z., Figg, W.D. Cancer Biol. Ther. (2002)
- Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Blagosklonny, M.V., Robey, R., Sackett, D.L., Du, L., Traganos, F., Darzynkiewicz, Z., Fojo, T., Bates, S.E. Mol. Cancer Ther. (2002)
- Cyclotherapy: protection of normal cells and unshielding of cancer cells. Blagosklonny, M.V., Darzynkiewicz, Z. Cell. Cycle (2002)
- Are p27 and p21 cytoplasmic oncoproteins?. Blagosklonny, M.V. Cell. Cycle (2002)
- From the war on cancer to translational oncology. Blagosklonny, M.V. Cancer Biol. Ther. (2002)